Last C$0.05 CAD
Change Today 0.00 / 0.00%
Volume 138.2K
VPT On Other Exchanges
Symbol
Exchange
Venture
OTC US
As of 10:17 AM 02/27/15 All times are local (Market data is delayed by at least 15 minutes).

ventripoint diagnostics ltd (VPT) Snapshot

Open
C$0.05
Previous Close
C$0.05
Day High
C$0.05
Day Low
C$0.05
52 Week High
03/10/14 - C$0.17
52 Week Low
12/9/14 - C$0.04
Market Cap
9.3M
Average Volume 10 Days
92.1K
EPS TTM
C$-0.0031
Shares Outstanding
185.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for VENTRIPOINT DIAGNOSTICS LTD (VPT)

Related News

No related news articles were found.

ventripoint diagnostics ltd (VPT) Related Businessweek News

No Related Businessweek News Found

ventripoint diagnostics ltd (VPT) Details

VentriPoint Diagnostics Ltd., a medical device company, engages in the development and commercialization of diagnostic tools to monitor patients with heart disease. The company offers Ventripoint Medical System that is used to generate critical volume and functional measurements of the right ventricle. VentriPoint Diagnostics Ltd. is based in Bellevue, Washington.

ventripoint diagnostics ltd (VPT) Top Compensated Officers

Chief Executive Officer, President, Director ...
Total Annual Compensation: $247.9K
Chief Financial Officer
Total Annual Compensation: $72.6K
Compensation as of Fiscal Year 2013.

ventripoint diagnostics ltd (VPT) Key Developments

Ventripoint Diagnostics Ltd. Installs its VMS Heart Analysis System at Shandong Provincial Hospital

VentriPoint Diagnostics Ltd. announced that it has installed its VMSTM heart analysis system at the Shandong Provincial Hospital (SPH) in Jinan, China and has examined a number of patients. The SPH does 300 cardiac ultrasound exams a day and has nine other hospitals in its group.

Ventripoint Diagnostics Ltd. Appoints Alan Rabinowitz to the Board of Directors

VentriPoint Diagnostics Ltd. announced the appointment of Dr. Alan Rabinowitz to the Board of Directors. Dr. Alan Rabinowitz is a cardiologist and President of the Medical Staff of St. Paul's Hospital, Vancouver, and Clinical Associate Professor in the Division of Cardiology at the University of British Columbia. He is the co-founder of PHEMI Health Systems and serves as Chief Medical Officer and a Director on the Board of that company. Dr. Rabinowitz also serves as a consultant to numerous medical institutions and organizations globally on medical innovation and system improvement, and has initiated and facilitated multiple international physician educational and practice exchanges.

VentriPoint Diagnostics Ltd. Provides Corporate Update

Ventripoint Diagnostics Ltd. provided corporate update. The clinical trial at Montefiore Hospital in New York City has begun and 17 patients have been enrolled to date. The study is designed to show that functional RV analysis, using the VMS on patients with left-heart failure, can aid in identifying patients who will be re-admitted to hospital within 30 days of initial discharge. The national average for the United States is 26% of patients return within 30 days. The Affordable-Care Act made cardiac re-admission rates a major metric for hospitals to improve. In 2013, approximately 2,300 hospitals had unacceptable re-admission rates and paid penalties totaling $330 million at the current 1% level of total billings to Medicare. In 2014, there were still roughly 2,300 hospitals with unacceptable re-admission rates and the penalty increased to 2%. On October 1, 2014, the third year of the program started and the penalty was increased to the 3% level. The Company has done an analysis of the effect of a 5% reduction in re-admission rates (from 26% to 21%) and determined the average hospital would benefit with $1.3 million in new or recovered revenue from better bed and MRI usage, as well as recovery of penalties and re-imbursements for the VMS procedures themselves. The study is ongoing and an interim analysis will be done once a sufficient number of patients has completed the 30 day period. The study will also look at 90 day re-admission rates to determine additional benefits from functional RV analysis.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VPT:CN C$0.05 CAD 0.00

VPT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for VPT.
View Industry Companies
 

Industry Analysis

VPT

Industry Average

Valuation VPT Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 166.0x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 165.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VENTRIPOINT DIAGNOSTICS LTD, please visit www.ventripoint.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.